Effects of Docosahexanoic Acid on Gut Microbiota and Fecal Metabolites in HIV-Infected Patients With Neurocognitive Impairment: A 6-Month Randomized, Double-Blind, Placebo-Controlled Trial

Frontiers in Nutrition

Nutrition

Yingying Ding¹  Ruizi Shi¹  Keran Wang¹  Xiaohui Xu¹  Shiying Yuan¹  Bowen Zhu¹  Jing Li¹  Na He²  Haijiang Lin³  Ruihua Dong⁴  Ding Ding⁵  Weiwei Shen⁶  Xiaoxiao Chen⁶ 

[1] Department of Epidemiology, School of Public Health, and the Key Laboratory of Public Health Safety of Ministry of Education, Fudan University, Shanghai, China;Department of Epidemiology, School of Public Health, and the Key Laboratory of Public Health Safety of Ministry of Education, Fudan University, Shanghai, China;Shanghai Institute of Infectious Diseases and Biosafety, Fudan University, Shanghai, China;Department of Epidemiology, School of Public Health, and the Key Laboratory of Public Health Safety of Ministry of Education, Fudan University, Shanghai, China;Taizhou City Center for Disease Control and Prevention, Taizhou City, China;Department of Nutrition and Food Hygiene, School of Public Health, Fudan University, Shanghai, China;Department of Epidemiology, School of Public Health, and the Key Laboratory of Public Health Safety of Ministry of Education, Fudan University, Shanghai, China;Institute of Neurology, Huashan Hospital, Fudan University, Shanghai, China;Taizhou City Center for Disease Control and Prevention, Taizhou City, China;

关键词: docosahexanoic acid (DHA);    HIV;    neurocognitive impairment (NCI);    gut microbiota;    fecal metabolites;   

DOI  :  10.3389/fnut.2021.756720

 received in 2021-09-15, accepted in 2021-12-16,  发布年份 2022

来源: Frontiers

【 摘 要 】

Neurocognitive impairment (NCI) and gut microbiota dysbiosis are prevalent in patients with HIV infection. Docosahexanoic acid (DHA) supplementation may alleviate multiple neurocognitive diseases symptoms and plays important role in regulating gut microbiota. However, it is not known whether DHA algae oil supplements can alleviate neurocognitive impairment (NCI) and regulate gut microbiota and fecal metabolites. A randomized, double-blind, placebo-controlled trial was performed on 68 HIV-infected patients with NCI. Participants were randomized to receive a 3.15 g daily DHA algae oil supplement or placebo for 6 months. We collected blood and fecal samples from these patients before and after the trial. Mini mental state examination (MMSE) and neuropsychological tests (NP tests) were administered to assess the cognitive status of participants. The influence of DHA algae oil on the gut microbiota, fecal metabolomics, plasma proinflammatory, and oxidative stress factors was also investigated. There were no significant changes in NCI according to global diagnosis score (GDS) and MMSE score within the two groups, while patients receiving DHA had improvement in several blood lipids, pro-inflammatory and oxidative stress factors. The DHA supplement increased α-diversity indexes, increased abundances of Blautia, Bifidobacterium, Dorea, Lactobacillus, Faecalibacterium, Fusobacterium, and Agathobacter, and decreased abundances of Bacteroides and Prevotella_9. Furthermore, DHA supplement was correlated with improved fecal lipid metabolites as indicated by ceramides, bile acids, glycerophospholipids. In addition, the DHA supplement was associated with altered cholesterol metabolism and purine metabolism pathways. A daily supplement of DHA algae oil for 6 months has been shown to promote favorable transformations in gut microbiota, profiles of fecal metabolomic, and factors responsible for proinflammatory and oxidative stress, which might be beneficial for the prognosis of HIV-infected patients with NCI in the long-term.Clinical Trial Registrationhttps://clinicaltrials.gov/ct2/show/NCT04242004, identifier: NCT04242004.

【 授权许可】

Unknown   
Copyright © 2022 Dong, Lin, Ding, Chen, Shi, Yuan, Li, Zhu, Xu, Shen, Wang, Ding and He.